IMPORTANT SAFETY INFORMATION

WARNING: RISK OF ANAPHYLAXIS

Life-threatening anaphylactic reactions have occurred in some patients during and up to 24 hours after ELAPRASE infusions. Anaphylaxis, presenting as respiratory distress, hypoxia, hypotension, urticaria and/or angioedema of throat or tongue have been reported to occur during and after ELAPRASE infusions, regardless of duration of the course of treatment. Closely observe patients during and after ELAPRASE administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.

WARNING: RISK OF ANAPHYLAXIS

Life-threatening anaphylactic reactions have occurred in some patients during and up to 24 hours after ELAPRASE infusions. Anaphylaxis, presenting as respiratory distress, hypoxia, hypotension, urticaria and/or angioedema of throat or tongue have been reported to occur during and after ELAPRASE infusions, regardless of duration of the course of treatment. Closely observe patients during and after ELAPRASE administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.

The risk of anaphylaxis is not the only warning or precaution for Elaprase. Additional warnings and precautions are the risks of: hypersensitivity, serious adverse reactions, and antibody development in patients with severe genetic mutations; acute respiratory complications; and, acute cardiorespiratory failure. Please see the Important Safety Information below and the full Prescribing Information.

Adverse Reactions

Clinical Trial in Patients ≥ 5 Years of Age

In clinical trials with 96 male patients age 5 and older with Hunter Syndrome, the most common adverse reactions (occurring in more than 10% of patients) following ELAPRASE treatment were hypersensitivity (allergic) reactions, and included rash, hives, itching, ﬂushing, fever, and headache. The most frequent serious adverse reactions were episodes of insuﬃcient oxygen supply, called hypoxia.

Adverse reactions that occurred in at least 9% of patients in the ELAPRASE 0.5 mg/kg once-weekly group and with a higher incidence than in the placebo group were:

Adverse Reaction

ELAPRASE (0.5 mg/kg weekly) N=32 n (%)

Placebo N=32 n (%)

Headache

9 (28%)

8 (25%)

Itching (Pruritis)

8 (25%)

3 (9%)

Hives (Urticaria)

5 (16%)

0 (0%)

Musculoskeletal Pain

4 (13%)

1 (3%)

Cough

3 (9%)

1 (3%)

Diarrhea

3 (9%)

1 (3%)

Hypersensitivity reactions were reported in 69% of patients who received once-weekly treatment with ELAPRASE.

Additional adverse reactions that occurred in at least 9% of patients (≥3 patients) in the ELAPRASE 0.5 mg/kg every other week group and with a higher incidence than in the placebo group included: rash (19%), ﬂushing (16%), fatigue (13%), rapid heart rate (9%), and chills (9%).

Adverse Reactions Reported Since Approval of ELAPRASE

Late-emergent symptoms and signs of anaphylactic reactions have occurred up to 24 hours after initial treatment and recovery from an initial anaphylactic reaction. In addition, patients experienced repeated anaphylaxis over a two- to four-month period, up to several years after initiating ELAPRASE treatment.

ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older. The safety and eﬃcacy of ELAPRASE have not been established in pediatric patients less than 16 months of age.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF ANAPHYLAXIS

Life-threatening anaphylactic reactions have occurred in some patients during and up to 24 hours after ELAPRASE infusions. Anaphylaxis, presenting as respiratory distress, hypoxia, hypotension, urticaria and/or angioedema of throat or tongue have been reported to occur during and after ELAPRASE infusions, regardless of duration of the course of treatment. Closely observe patients during and after ELAPRASE administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.

If anaphylactic or other acute reactions occur, immediately discontinue the infusion of ELAPRASE and initiate appropriate medical treatment. Observe patients closely for an appropriate period of time after administration of ELAPRASE, taking into account the time to onset of anaphylaxis seen in premarketing clinical trials and postmarketing reports. Inform patients of the signs and symptoms of anaphylaxis, and instruct them to seek immediate medical care should signs and symptoms occur. When severe reactions have occurred during clinical trials, subsequent infusions were managed with antihistamine and/or corticosteroids prior to or during infusions, a slower rate of ELAPRASE infusion, and/or early discontinuation of the ELAPRASE infusion.

Patients with compromised respiratory function or acute febrile or respiratory illness may be at higher risk of life-threatening complications from hypersensitivity reactions. Careful consideration should be given to the patient’s clinical status prior to administration of ELAPRASE and consider delaying the ELAPRASE infusion.

Risk of Acute Cardiorespiratory Failure:

Caution should be exercised when administering ELAPRASE to patients susceptible to ﬂuid overload, or patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function for whom ﬂuid restriction is indicated. These patients may be at risk of serious exacerbation of their cardiac or respiratory status during infusions. Appropriate medical support and monitoring measures should be readily available during ELAPRASE infusion, and some patients may require prolonged observation times that should be based on the individual needs of the patient.

Adverse Reactions:

In clinical trials, the most frequent serious adverse reactions following ELAPRASE treatment were hypoxic episodes. Other notable serious adverse reactions that occurred in the ELAPRASE-treated patients but not in the placebo-treated patients included one case each of: cardiac arrhythmia, pulmonary embolism, cyanosis, respiratory failure, infection, and arthralgia.

The most common adverse reactions occurring in at least three patients (≥9%) aged ﬁve years and older were headache, pruritus, musculoskeletal pain, urticaria, diarrhea, and cough. The most common adverse reactions occurring in at least three patients (≥10%) aged seven years and younger were pyrexia, rash, vomiting, and urticaria. In all clinical trials, the most common adverse reactions requiring medical intervention were hypersensitivity reactions, and included rash, urticaria, pruritus, ﬂushing, pyrexia, and headache.

Immunogenicity:

In clinical trials in patients 5 years and older, 32 of 63 (51%) patients tested positive for anti-idursulfase IgG antibodies (Ab) at least one time. Of the 32 Ab-positive patients, 23 of 32 (72%) tested positive for Ab at three or more diﬀerent time points (persistent Ab). The incidence of hypersensitivity reactions was higher in patients who tested positive for Ab than those who tested negative.

Thirteen of 32 (41%) Ab-positive patients also tested positive for antibodies that neutralize idursulfase uptake into cells (neutralizing antibodies, NAb) or enzymatic activity at least one time, and 8 (25%) of Ab-positive patients had persistent NAb. There was no clear relationship between the presence of either Ab or NAb and therapeutic response.

In the clinical trial in patients 7 years and younger, 19 of 28 (68%) patients treated with ELAPRASE 0.5 mg/kg once weekly tested Ab-positive, with 16 of 19 (84%) having persistent Ab. In addition, 15 of 19 (79%) Ab-positive patients tested positive for NAb, with 14 of 15 (93%) having persistent NAb.

Postmarketing Experience:

Late-emergent symptoms and signs of anaphylactic reactions have occurred up to 24 hours after initial treatment and recovery from an initial anaphylactic reaction. In addition, patients experienced repeated anaphylaxis over a two- to four-month period, up to several years after initiating ELAPRASE treatment.

ELAPRASE and OnePath and the associated logos are registered trademarks of Shire or its affiliates. All other trademarks are the property of their respective owners. All content of this website including text, images, graphics, sound ﬁles, and their arrangement, belongs to Shire and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modiﬁed, or posted to other sites. This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Terms of Use and online Privacy Policy for more information. While Shire makes reasonable eﬀorts to include accurate, up-to-date information on the site, Shire makes no warranties or representations as to its accuracy. Shire assumes no liability for any errors or omissions in the content of the site.

ARE YOU A HEALTHCARE PROFESSIONAL?

The information in this section of elaprase.com is intended for U.S. healthcare professionals only.

You are about to leave this website.

Please be advised that Shire Pharmaceuticals has no control over the content or presentation of the site you are about to view. Shire's Privacy Policy does not apply to the website you are about to visit.

Shire respects your personal information. All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained in our Privacy Policy Statement. We encourage you to read our Privacy Policy Statement by clicking on this link. This consent will be in effect until such a time as you opt out of the program.